Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900579 | 1.00 | NOD2 (0.44) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL23092713 | 0.91 | NOD2 (0.44) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL5951286 | 0.87 | NR1H2 (0.39) | KMT2AKDM4ENR1H2GABRG2GABRB3 | |
| SCHEMBL29631979 | 0.87 | NR1H2 (0.39) | KMT2AKDM4ENR1H2GABRG2GABRB3 | |
| SCHEMBL28679819 | 0.84 | NR1H2 (0.38) | NR1H2GABRG2GABRB3GABRA5AURKA | |
| SCHEMBL24894603 | 0.83 | NOD2 (0.62) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL29827958 | 0.83 | NOD2 (0.62) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL5623839 | 0.82 | NOD2 (0.52) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL12685162 | 0.81 | NR1H2 (0.39) | NR1H2GABRG2GABRB3GABRA5 | |
| SCHEMBL13173591 | 0.81 | NOD2 (0.46) | NOD2NOD1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4464705-A1 | SALT OF ROCK INHIBITOR, CRYSTAL FORM OF SALT, COMPOSITION, AND PHARMACEUTICAL USE | Wuhan Createrna Science and Technology Co.,Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| WO-2023134688-A1 | SALT OF ROCK INHIBITOR, CRYSTAL FORM OF SALT, COMPOSITION, AND PHARMACEUTICAL USE | 武汉朗来科技发展有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134688-A1 | SALT OF ROCK INHIBITOR, CRYSTAL FORM OF SALT, COMPOSITION, AND PHARMACEUTICAL USE | 武汉朗来科技发展有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| EP-1768979-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
| EP-0186431-B1 | ANTI-HYPERTENSIVE OCTAHYDRO-6-AZAINDOLE DIPEPTIDE DERIVATIVES | Pfizer Limited (GB) | 1988-02-03 | — | — | EP | disclosed |
| US-4711882-A | INHIBITOR OF ANGIOTENSIN CONVERTING ENZYME; HYPOTENSIVE AND CARDIOTONIC AGENTS | PFIZER INC. (US) | 1987-12-08 | — | — | US | disclosed |
| CN-85109243-A | Method for preparing antihypertensive octahydro-6-azaindole dipeptide derivative | — | 1986-09-17 | — | — | CN | disclosed |
| EP-0186431-A1 | Anti-hypertensive octahydro-6-azaindole dipeptide derivatives | Pfizer Limited (GB) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, ROCK2, RHOT2 | NOD2 4306/4885NOD1 3679/4885MEN1 371/4885 |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | PNPO, NLRP3, CHRM3 | NOD2 244/4885NOD1 13/4885MEN1 2674/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | NOD2 2154/4885NOD1 2798/4885MEN1 3722/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | NOD2 2154/4885NOD1 2798/4885MEN1 3722/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | NOD2 2154/4885NOD1 2798/4885MEN1 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.